

- 214 Hovstadius P, Larsson R, Jonsson E, Skov T, Kissmeyer AM, Krasilnikoff K, et al. *Clin Cancer Res* 2002;**8**:2850.
- 215 Karin M, Yamamoto Y, Wang QM. *Nature Rev Drug Discov* 2004;**3**:17.
- 216 Liu S, Chen ZJ. *Cell Res* 2011;**21**:6.
- 217 Tandle A, Hanna E, Lorang D, Hajitou A, Moya CA, Pasqualini R, et al. *Cancer* 2009;**115**:128.
- 218 Chen B, Shanshan C, Zhang Y, Wang X, Liu J, Hui X, et al. *BMC Cell Biol* 2009;**10**:63.
- 219 Owens TW, Gilmore AP, Streuli CH, Foster FM. *J Carcinogen Mutagen* 2013;**S14**:004.
- 220 Du C, Fang M, Li Y, Li L, Wang X. *Cell* 2000;**102**:33.
- 221 Chai J, Du C, Wu JW, Kyin S, Wang X, Shi Y. *Nature* 2000;**406**:855.
- 222 Wang H, Guo Q, Jiang Y, Liu E, Zhao Y, Wang H, et al. *Adv Funct Mater* 2013;**23**:6068.
- 223 Krepler C, Chunduru SK, Halloran MB, He X, Xiao M, Vultur A, et al. *Clin Cancer Res* 2013;**19**:1784.
- 224 See the pipeline of Novartis Oncology at <http://www.novartis.com>. Novartis, 2011.
- 225 Petrucci E, Pasquini L, Bernabei M, Saulle E, Biffoni M, Accarpio F, et al. *PLoS One* 2012;**7**:e35073.
- 226 Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, et al. *J Med Chem* 2011;**54**:2714.
- 227 Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S, et al. *Mol Cancer Ther* 2011;**10**:902.
- 228 Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, et al. *J Clin Oncol* 2009;**27**:4461.
- 229 Mita AC, Mita MM, Nawrocki ST, Giles FJ. *Clin Cancer Res* 2008;**14**:5000.
- 230 Fulda S, Vucic D. *Nature Rev Drug Discov* 2012;**11**:109.
- 231 Cao C, Mu Y, Hallahan DE, Lu B. *Oncogene* 2004;**23**:7047.
- 232 Du ZX, Zhang HY, Gao DX, Wang HQ, Li YJ, Liu GL. *Exp Mol Med* 2006;**38**:230.
- 233 Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, et al. *Blood* 2011;**118**:2191.
- 234 Ohnishi K, Scuric EC, Schiesti RH, Okamoto N, Takahashi A, Ohnishi T. *Radiat Res* 2006;**166**:454.
- 235 Pennati M, Folini M, Zaffaroni N. *Carcinogenesis* 2007;**28**:1133.
- 236 Chaudhury S, Welch TR, Blagg BS. *ChemMedChem* 2006;**1**:1331.
- 237 Giaccia A, Siim BG, Johnson RS. *Nature Rev Drug Discov* 2003;**2**:1.
- 238 Ali MMU, Roe SM, Vaughan CK, Meyer P, Panaretou B, Piper PW, et al. *Nature* 2006;**440**:1013.
- 239 Kitson RS, Chang C-H, Xiong R, Williams HEL, Davis AL, Lewis W, et al. *Nature Chem* 2013;**5**:307.
- 240 Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG. *Clinical lymphoma, myeloma & leukemia* 2011;**11**:17.
- 241 Burger AM, Fiebig HH, Stinson SF, Sausville EA. *Anticancer Drugs* 2004;**15**:377.
- 242 Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, et al. *J Clin Oncol* 2010;**28**:4953.
- 243 Chiosis G, Lopes EC, Solit D. *Curr Opin Invest Drugs* 2006;**7**:534.
- 244 Dickson MA, Okuno SH, Keohan ML, Maki RG, D'Adamo DR, Akhurst TJ, et al. *Ann Oncol* 2013;**24**:252.
- 245 Sharp SY, Prodromou Ch, Boxall K, Powers MV, Holmes GB, Thomas PM, et al. *Mol Cancer Ther* 2007;**6**:1198.
- 246 Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. *Cancer Res* 2008;**68**:2850.
- 247 Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, et al. *J Med Chem* 2008;**51**:196.
- 248 Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, et al. *Mol Cancer Ther* 2012;**11**:475.
- 249 (a) Murray CW, Carr MG, Callaghan O, Chessari G, Congreve M, Cowan S, et al. *J Med Chem* 2010;**53**:5942; (b) Woodhead AJ, Angove H, Carr MG, Chessari G, Congreve M, Coyle JE, et al. *J Med Chem* 2010;**53**:5956.
- 250 Menezes DL, Taverna P, Jensen MR, Abrams T, Stuart D, Yu GK, et al. *Mol Cancer Ther* 2012;**11**:730.
- 251 Schultz CR, Golembieski WA, King DA, Brown SL, Brodie C, Rempel SA. *Mol Cancer* 2012;**11**:20.
- 252 Zielinski R, Chi KN. *Future Oncol* 2012;**8**:1239.
- 253 Caudill MM, Li Z. *Expert Opin Biol Ther* 2001;**1**:539.